1609P - Physical activity (PA) and physical fitness (PF) in lymphoma patients before during and after chemotherapy (PAFILP): a prospective observational pil...

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Lymphomas
Supportive Care
Presenter Pascal Wolter
Authors P. Wolter1, N. Vermaete2, D. Dierickx3, A. Janssens3, P. Schöffski1, G. Verhoef3, R. Gosselink2
  • 1Department Of General Medical Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 2Department Of Rehabilitation Sciences, KU Leuven, 3000 - Leuven/BE
  • 3Department Of Hematology, University Hospitals, 3000 - Leuven/BE



We performed a prospective longitudinal single-center pilot study to investigate physical activity (PA) and physical fitness (PF) in Hodgkin Lymphoma (HL) and Non-Hodgkin-Lymphoma (NHL) patients before, during and after first-line systemic chemotherapy. Further aims were to correlate different patient-, disease-, and treatment-related factors with the possible decline or increase of PA and PF and to identify patients at risk of developing a significant decline in PA and PF who might be candidates for an individualized exercise training program.


PA was assessed with an activity monitor (Dynaport MiniMod McRoberts, The Hague, The Netherlands), PF by incremental cycle ergometry and by a 6 minute walking test (6MWD). Isometric quadriceps strength was measured using a Cybex II dynamometer (Lumex, Bay Shore, United States). Pulmonary function tests, electrocardiogram, echocardiography, blood pressure measurements were routinely performed.


The pilot study involved a total of 22 lymphoma patients (♂: 19, ♀: 3, median age 57 years, NHL: 14, HL: 8) from 10/2010 to 01/2012. At baseline PA, 6MWD, maximal inspiratory pressure, quadriceps strenght, diffusion capacity at pulmonary function tests were significantly lower than predicted. In contrast, forced expiratory volume in one second (FEV1), forced vital capacity (FVC), maximal oxygen consumption (VO2max), maximal expiratory force and hand grip force were not significantly different. We observed a broad variation in the different test results between patients at baseline. After 2-3 cycles of chemotherapy we did not identify a significant decrease in PA, whereas VO2max decreased significantly after 2-3 cycles but recovered after completion of chemotherapy (6-8 cycles). Importantly, a huge interpatient variability could be observed at all different time points.


Preliminary results of the PAFILP pilot study suggest that levels of PA and PF probably evolve very differently between lymphoma patients. The study is ongoing to identify possible risk factors predictive for decline in PA and PF. Such a screening tool would allow us to identify early in the course of treatment patients at risk of developing a significant decline in PA and PF who might benefit from an individualized exercise training program.


All authors have declared no conflicts of interest.